Preemptive antiviral therapy for CMV infection in allogeneic stem cell transplant recipients guided by the viral doubling time in the blood

Bone Marrow Transplantation

Volumn 51, Issue 5, 2016, Pages 718-721

  Solano, C ^a,b   Gimenez E ^a   Pinana J L ^a   Vinuesa, V ^a   Poujois, S ^a   Zaragoza, S ^a   Calabuig, M ^a   Navarro, D ^a,b  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; VALGANCICLOVIR; VIRUS DNA; GANCICLOVIR;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; BODY WEIGHT; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FEMALE; GLOMERULUS FILTRATION; GRAFT RECIPIENT; HUMAN; INFECTION PREVENTION; LETTER; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PHYSICAL PARAMETERS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; VIRAL DOUBLING TIME; VIRUS IDENTIFICATION; VIRUS LOAD; YOUNG ADULT; ADOLESCENT; ALLOTRANSPLANTATION; BLOOD; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; PHYSIOLOGY; VIRUS REPLICATION;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FEMALE; GANCICLOVIR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; TRANSPLANTATION, HOMOLOGOUS; VIRUS REPLICATION; YOUNG ADULT;

EID: 84949293627     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2015.303     Document Type: Letter

References (15)

1. Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 2009; 113: 5711-5719.
2. Emery V, Zuckerman M, Jackson G, Aitken C, Osman H, Pagliuca A et al. Management of cytomegalovirus infection in haemopoietic stem cell transplantation. Br J Haematol 2013; 162: 25-39.
3. Solano C, Muñoz-Cobo B, Giménez E, Remigia MJ, Amat P, Clari MA et al. Pre-emptive antiviral therapy for active CMV infection in adult allo-SCT patients guided by plasma CMV DNAemia quantitation using a real-time PCR assay: clinical experience at a single center. Bone Marrow Transplant 2013; 48: 1010-1012.
4. Pérez Romero P, Blanco P, Giménez E, Solano C, Navarro D. An update on the management and prevention of cytomegalovirus infection following allogeneic hematopoietic stem cell transplantation. Future Virol 2015; 10: 113-134.
5. Solano C, de la Cmara R, Vzquez L, López J, Giménez E, Navarro D. Cytomegalovirus infection management in allogeneic stem cell transplant recipients: A National Survey in Spain. J Clin Microbiol 2015; 53: 2741-2744.
6. Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000; 355: 2032-2036.
7. Giménez E, Muñoz-Cobo B, Solano C, Amat P, Navarro D. Early kinetics of plasma cytomegalovirus DNA load in allogeneic stem cell transplant recipients in the era of highly sensitive real-time PCR assays: does it have any clinical value? J Clin Microbiol 2014; 52: 654-656.
8. Bravo D, Clari MÁ, Costa E, Muñoz-Cobo B, Solano C, Remigia MJ et al. Comparative evaluation of three automated systems for DNA extraction in conjunction with three commercially available real-time PCR assays for quantitation of plasma Cytomegalovirus DNAemia in allogeneic stem cell transplant recipients. J Clin Microbiol 2011; 49: 2899-2904.
9. Clari MÁ, Bravo D, Costa E, Muñoz-Cobo B, Solano C, Remigia MJ et al. Comparison of the new Abbott Real Time CMV assay and the Abbott CMV PCR Kit for the quantitation of plasma cytomegalovirus DNAemia. Diagn Microbiol Infect Dis 2013; 75: 207-209.
10. Muñoz-Cobo B, Solano C, Costa E, Bravo D, Clari MÁ, Benet I et al. Dynamics of cytomegalovirus (CMV) plasma DNAemia in initial and recurrent episodes of active CMV infection in the allogeneic stem cell transplantation setting: implications for designing preemptive antiviral therapy strategies. Biol Blood Marrow Transplant 2011; 17: 1602-1611.
11. Gimeno C, Solano C, Latorre JC, Hernndez-Boluda JC, Clari MA, Remigia MJ et al. Quantification of DNA in plasma by an automated real-time PCR assay (CMV PCR Kit, Abbott) for surveillance of active cytomegalovirus infection and guidance of pre-emptive therapy for allogeneic hematopoietic stem cell transplant recipients. J Clin Microbiol 2008; 46: 3311-3318.
12. Hayden RT, Gu Z, Sam SS, Sun Y, Tang L, Pound S et al. Comparative evaluation of three commercial quantitative cytomegalovirus standards by use of digital and real-time PCR. J Clin Microbiol 2015; 53: 1500-1505.
13. Fryer JF, Heath AB, Anderson R, Minor PD. Collaborative Study Group. Collaborative study to evaluate the proposed 1st WHO international standard for human cytomegalovirus (HCMV) for nucleic acid amplification (NAT)-based assays. WHO ECBS Report 2010. WHO/BS/ 10: 2138. World Health Organization: Geneva, Switzerland, 2010.
14. Pang XL, Fox JD, Fenton JM, Miller GG, Caliendo AM, Preiksaitis JK. American Society of Transplantation Infectious Diseases Community of Practice; Canadian Society of Transplantation Interlaboratory comparison of cytomegalovirus viral load assays. Am J Transplant 2009; 9: 258-268.
15. Scrucca L, Santucci A, Aversa F. Regression modeling of competing risk using R: an in depth guide for clinicians. Bone Marrow Transplant 2010; 45: 1388-1395.